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The Ca21/calmodulin-dependent endothelial cell myo-
sin light chain kinase (MLCK) triggers actomyosin con-
traction essential for vascular barrier regulation and
leukocyte diapedesis. Two high molecular weight MLCK
splice variants, EC MLCK-1 and EC MLCK-2 (210–214
kDa), in human endothelium are identical except for a
deleted single exon in MLCK-2 encoding a 69-amino acid
stretch (amino acids 436–505) that contains potentially
important consensus sites for phosphorylation by p60Src
kinase (Lazar, V., and Garcia, J. G. (1999) Genomics 57,
256–267). We have now found that both recombinant EC
MLCK splice variants exhibit comparable enzymatic ac-
tivities but a 2-fold reduction of Vmax, and a 2-fold in-
crease in K0.5 CaM when compared with the SM MLCK
isoform, whereas Km was similar in the three isoforms.
However, only EC MLCK-1 is readily phosphorylated by
purified p60Src in vitro, resulting in a 2- to 3-fold in-
crease in EC MLCK-1 enzymatic activity (compared with
EC MLCK-2 and SM MLCK). This increased activity of
phospho-MLCK-1 was observed over a broad range of
submaximal [Ca21] levels with comparable EC50 [Ca
21]
for both phosphorylated and unphosphorylated EC
MLCK-1. The sites of tyrosine phosphorylation cata-
lyzed by p60Src are Tyr464 and Tyr471 within the 69-resi-
due stretch deleted in the MLCK-2 splice variant. These
results demonstrate for the first time that p60Src-medi-
ated tyrosine phosphorylation represents an important
mechanism for splice variant-specific regulation of non-
muscle MLCK and vascular cell function.
The family of myosin light chain kinases (MLCK)1 expressed
in vertebrates are Ca21/calmodulin-regulated enzymes that
catalyze the transfer of phosphate from Mg21-ATP to a serine
residue (Ser19) of regulatory myosin light chain (MLC20) (1, 2).
Members of this MLCK family share structural similarity, with
a catalytic core that binds Mg21-ATP and MLC20 and a regu-
latory segment involved in Ca21/calmodulin-dependent activa-
tion. Comparisons of primary sequences deduced from cDNA
clones demonstrate that skeletal and cardiac muscle MLCK
isoforms represent gene products that differ from the gene
encoding the smooth muscle and nonmuscle MLCK isoforms
localized on human chromosome 3 (3–6). Furthermore, the
physiological role of the gene-specific MLCK isoforms differs
significantly in the regulation of actomyosin contraction. In
skeletal and cardiac muscles, Ca21 binds to the regulatory thin
filament protein complex containing troponin and tropomyosin
and thus allows actin to activate sarcomeric myosin Mg21-
ATPase. Although MLCK does not initiate muscle contraction
in these tissues, MLCK-mediated phosphorylation of MLC20
may potentiate the rate and extent of force development (7, 8).
In contrast, Ser19 phosphorylation of MLC20 by Ca
21/calmod-
ulin-dependent enzyme MLCK is essential for the initiation of
nonmuscle and smooth muscle contraction (1, 3, 9–11). In
specific nonmuscle tissues, such as the vascular endothelium,
this kinase is known to be involved in endothelial cell migra-
tion, cell retraction (12), endothelial cell barrier regulation (13),
transendothelial migration of neutrophils (14, 15), and possibly
apoptosis (16). The MLCK isoform abundantly expressed in
smooth muscle (SM MLCK) generally exists as a 130- to 150-
kDa protein that has been well characterized (for review see
Refs. 3 and 11). However, Western blot screening of a variety of
embryonic and adult smooth muscle and nonmuscle tissues
revealed expression of a high molecular weight MLCK variant
with electrophoretic mobility in the range of 208–214 kDa
(17–19). Garcia and colleagues (20) subsequently sequenced
the high molecular weight MLCK isoform cloned from a human
endothelial cell cDNA library, revealing an open reading frame,
which encodes a protein of 1914 amino acids. Both the low
molecular mass (130–150 kDa) and high molecular mass (208–
214 kDa) MLCK isoforms share essentially identical actin
binding, MLC binding, catalytic, and Ca21/CaM-regulatory do-
mains. The extreme C-terminal kinase-related protein (KRP)
domain, which binds myosin, is contained within both EC
MLCK and SM MLCK but can be also expressed as an inde-
pendent protein capable of stabilizing myofilaments in vitro (3,
21–23). The C-terminal half of the endothelial MLCK isoform
(residues 923–1914) exhibits 99.8% homology to the human low
molecular weight MLCK from hippocampus and substantial
homology to published SM MLCK sequences from rabbit (94%
homology), bovine (95% homology), and chicken (85% homol-
ogy) (5, 6, 24, 25). However, the exact biological function of the
922-amino acid N-terminal portion, which is unique to the high
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molecular weight MLCK isoform, is completely unknown. We
have previously found that increased levels of endothelial cell
protein tyrosine phosphorylation evoked by thrombin or diper-
oxovanadate are tightly linked to increased MLC20 phosphoryl-
ation, activation of actomyosin contraction, and a dramatic
decrease in endothelial cell barrier function (26, 27). Further
studies demonstrated that the increased kinase activity in
MLCK immunoprecipitates strongly correlated with increased
EC MLCK phosphorylation on tyrosine residues (26). Endothe-
lial cell MLCK was found to be stably associated with p60Src
kinase after stimulation (26), consistent with potential direct
regulation of endothelial MLCK activity by tyrosine phospho-
rylation. More recently, detailed analysis of MLCK transcripts
expressed in human endothelial cells revealed several splice
variants of the EC MLCK isoform with predominant expression
of the full-length isoform (MLCK-1) and a variant, which is
identical to MLCK-1 except for a deleted 69-residue stretch
(amino acid residues 437–505) encoded by a single exon
(MLCK-2) (28). Within this deleted 69-amino acid stretch is an
SH2-binding domain and consensus sites for phosphorylation
by the Src family kinases (Tyr464, Tyr485). To better understand
the role and significance of tyrosine phosphorylation and the
function of the novel N terminus in EC MLCK regulation, we
have expressed both EC MLCK-1 and EC MLCK-2 isoforms as
well as smooth muscle MLCK in the baculovirus system and
have characterized the biochemical properties of the purified
recombinant proteins. Furthermore, we have assessed the
phosphorylation of MLCK-1, MLCK-2, and SM MLCK by
p60Src kinase in vitro, mapped the p60Src-phosphorylation sites
to Tyr464 and Tyr471 of MLCK-1, and investigated the effects of
MLCK-1 phosphorylation by p60Src kinase on the MLCK enzy-
matic activity and regulation by Ca21/calmodulin. Our studies
indicate the novel up-regulation of high molecular weight en-
dothelial MLCK-1 isoform activity by p60Src-induced tyrosine




Chemicals used in these studies were obtained from Sigma Chemical
Co. (St. Louis, MO), unless otherwise specified. Restriction and modi-
fication enzymes were purchased from Amersham Pharmacia Biotech
(Arlington Heights, IL), Roche Molecular Biochemicals (Indianapolis,
IN), Life Technologies (Gaithersburg, MD), and Promega (Madison,
WI). Radioactive nucleotides, [g-32P]ATP and [g-33P]ATP, were ob-
tained from PerkinElmer Life Sciences (Boston, MA). MLCK inhibitor
(ML-7) and the p60Src inhibitor (PP2) were obtained from Calbiochem-
Novabiochem Corp. (La Jolla, CA). Purified p60C-src kinase was ob-
tained from Upstate Biotechnology (Lake Placid, NY). Sf9 and Hi5
insect cells (Invitrogen, Carlsbad, CA) were grown in serum-free Sf-900
II SFM media obtained from Life Technologies.
Recombinant Donor Plasmids for Baculovirus Expression
Smooth-muscle MLCK—A rabbit uterine smooth muscle MLCK
full-length cDNA in a pGEM vector (24) was a generous gift from
Dr. Patricia Gallagher (Indiana University). The plasmid was cut at the
Eco52I site, followed by blunt-ending with Klenow enzyme. The MLCK
insert was then released by digesting plasmid with XbaI, separated
from the vector by agarose gel electrophoresis, and purified using a
Prep-A-Gene (Bio-Rad, Hercules, CA) kit. The smooth muscle MLCK
cDNA was ligated with the pFastBac Hta baculovirus donor plasmid
(Bac-To-Bac baculovirus expression system, Life Technologies), which
had been digested with StuI and XbaI enzymes.
Nonmuscle MLCK-1 and MLCK-2—MLCK-2 cDNA was obtained
from human umbilical vein endothelial cells (HUVEC) by RT-PCR,
amplified, and subcloned as described earlier (28), using sense primer
59-ACT GAA TTC ACC ATG GGG GAT GTG AAG CTG and antisense
primer 59-GTC AGA ATT CTT GTT TCA CTC TTC TTC CTC TTC C,
both containing an EcoRI site. The EC MLCK-2 cDNA was inserted into
pFastBac Hta vector at the EcoRI site. To generate MLCK-1 cDNA, an
;1.85-kb 59-end fragment of HUVEC MLCK was amplified by RT-PCR
using a SuperScript preamplification system (Life Technologies). The
first-strand cDNA was synthesized from HUVEC total RNA with
oligo-dT primer. The PCR primers were as follows, sense: 59-ACT GCG
GCC GCA CCA TGG GGG ATG TGA AGC TG (NotI restriction site
followed by HUVEC MLCK-specific 59-end sequence), and antisense:
59-GTA CTC ACT CTT CCT GCT ACT C (;1.85-kb downstream HU-
VEC MLCK sequence). The same region (with a 207-bp deletion com-
pared with EC MLCK-1) of the nonmuscle MLCK-2/pFastBac Hta plas-
mid was excised and replaced with this PCR-amplified fragment
encoding the N-terminal portion of MLCK-1. Briefly, the PCR product
was digested with NotI, blunt-ended, and cut by BlpI. The respective
;1.66-kb fragment from the nonmuscle MLCK-2/pFastBac Hta plasmid
was excised with EheI and BlpI, and separated on agarose gel. The
PCR-amplified 59-end fragment of MLCK-1 and the 39-end MLCK re-
gion previously subcloned into pFastBac Hta vector were ligated to
create the recombinant donor plasmid of the whole EC MLCK-1 coding
region reported previously (20). All three constructs (SM MLCK, EC
MLCK-1, and EC MLCK-2) were verified by restriction analysis, PCR,
and complete sequencing.
Recombinant Regulatory Myosin Light Chain—A plasmid pET3-
MLC encoding rabbit vascular smooth muscle regulatory MLC was
generously provided by Dr. Patricia Gallagher (Indiana University) and
amplified by PCR using primers with unique restriction sites for direc-
tional cloning, MLC-sense-EcoRI: 59-TGC TTT GAA TTC ATG TCC
AGC AAG CGG GCC AAA GCC AAG-39, and MLC-antisense- XbaI:
59-AAG GAC TCT AGA CTA GTC GTG TTT ATC CTT GGC GCC
ATG-39, and then ligated with the pFastBac Hta baculovirus donor
plasmid (Bac-To-Bac baculovirus expression system), which had been
digested with EcoRI and XbaI enzymes.
Baculovirus Expression of MLC and MLCK Isoforms
Human endothelial cell MLCK-1 and MLCK-2, rabbit smooth muscle
MLCK and MLC recombinant baculovirus stocks were prepared using
the Bac-To-Bac baculovirus expression system (Life Technologies) ac-
cording to manufacturer’s instructions. The system uses site-specific
transposition of foreign genes into a baculovirus shuttle vector, bacmid,
propagated in Escherichia coli. Sf9 and Hi5 insect cell suspension
cultures at 2 3 106 cells/ml were infected with the respective viral stock
at a multiplicity of infection range of 0.1–10, and after 1-h incubation,
diluted 5-fold with fresh media and grown for 2–4 days at 28 °C with
continuous shaking. The optimal conditions varied for the three differ-
ent MLCK isoforms expressed (not shown). For large scale expression
and purification, Sf9 cells were infected with baculovirus (multiplicity
of infection 5 1), and the cells producing SM MLC, rabbit SM MLCK, or
human endothelial MLCK-1 and -2 were harvested. The recombinant
MLCK and MLC proteins contained a histidine tag at their N-terminal
region introduced during subcloning MLCK cDNAs into the pFastBac
Hta baculovirus donor vector. Expression of the MLCK isoforms was
confirmed by SDS-polyacrylamide gel electrophoresis (29) and Western
blot (30) using MLCK- specific D119 antiserum (31) or commercial
anti-His tag antibodies.
Purification of Recombinant Proteins
For the isolation of the recombinant MLCK isoforms or MLC, the
infected Sf9 cells were harvested by centrifugation at 3000 3 g for 5 min
and frozen at 280 °C. Frozen insect cells were lysed (1:5 w/v ratio) in
ice-cold lysis buffer (50 mM Tris-HCl, pH 8.5, 5 mM 2-mercaptoethanol,
100 mM KCl, 1 mM phenylmethylsulfonyl fluoride, and 1% Nonidet
P-40) at 4 °C for 2 min. The lysate was centrifuged at 10,000 3 g for 10
min, and the supernatant was loaded onto Ni-NTA resin (Qiagen, Santa
Clarita, CA). After a wash step with buffer A (20 mM Tris-HCl, pH 8.5,
500 mM KCl, 5 mM 2-mercaptoethanol, 10% glycerol), the expressed
MLCK isoforms were eluted with 100 mM imidazole, 20 mM Tris-HCl,
pH 8.5, 100 mM KCl, 5 mM 2-mercaptoethanol, 10% glycerol. The pro-
tein concentration was determined by Bio-Rad protein assay. The yield
of MLCK isoforms ranged from 1.5 to 4 mg of MLCK from a 10-g Sf9 cell
pellet. The purified enzymes were aliquoted and stored at 280 °C.
Verification and Characterization of MLCK Constructs
Human endothelial MLCK-1 and MLCK-2 splice variants as well as
the rabbit smooth muscle MLCK isoform cDNAs were subcloned into
baculovirus vector pFastBac Hta as described above. The alternatively
spliced regions in MLCK-1 and MLCK-2 mRNAs were verified by PCR
amplification (not shown) using primers located upstream and down-
stream of nucleotides 1428–1634 as well as by complete sequencing of
the MLCK-1 and MLCK-2 cDNA inserts. Translation of completely
sequenced cDNA inserts encoding EC MLCK splice variants revealed
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four amino acid residue differences between the unique N-terminal
sequence of the EC MLCK-1 and MLCK-2 (Phe629, Cys681, Gly714, and
Leu806) and the previously reported EC MLCK cDNA sequence (Gen-
Banky accession number U48959). These sequence differences, which
may represent polymorphisms within the human MLCK gene, did not
involve either the consensus sequence for potential tyrosine phospho-
rylation catalyzed by p60Src (Tyr464, Tyr471, Tyr485), the putative SH2-
binding sites (Tyr59, Tyr464), the SH3 domains (Pro314-Arg318, Arg373-
Pro379) previously proposed for EC MLCK (26, 28), and did not affect
MLCK enzymatic properties (shown below). Rigorous analysis of the
cDNA sequences encoding the C terminus of EC MLCK common to both
high and low molecular weight MLCK isoforms, revealed three vari-
ances (Phe925/Leu, Ala1179/Val, and Lys1233/Glu) in the baculovirus-
expressed recombinant MLCK-1 and MLCK-2 isoforms that do not
correspond to GenBanky accession number 48959 or to homologous
regions of the reported human, rabbit, and bovine SM MLCK variants,
respectively (6, 24, 25). Leu925 resides within the putative actin-binding
domain spanning residues 910–1036 of MLCK-1, whereas Val1179 and
Glu1233 do not lie within functional domains described for smooth mus-
cle MLCK (32).
Myosin Light Chain Phosphorylation Assays
Baculovirus-expressed SM MLC was used as a substrate after His-
tag excision by rTEV protease. In addition, several types of recombinant
Xenopus regulatory MLC, including wild type MLC (Ser19Thr18) and
Ser19Ala18 and Ala19Thr18 mutants expressed in E. coli (33) were used
as substrates in studies of EC MLCK substrate specificity. The purified
MLCKs were diluted in 50 mM MOPS, pH 7.4, 10 mM Mg21 acetate,
0.05% 2-mercaptoethanol containing 1 mg/ml bovine serum albumin to
a 1.25 3 10211 M final assay concentration. The MLCK activity was
determined by measuring 32P incorporation into the regulatory MLC
used as substrate. The MLCK kinase assays were performed in 50 mM
MOPS, pH 7.4, 10 mM Mg21-acetate, 0.025% 2-mercaptoethanol, in the
presence 0.3 mM CaCl2, 10
26 M calmodulin, 1027 M [g-32P]ATP at 0.5
Ci/mmol specific activity, and 1.25–15 3 1026 M myosin light chain at
22 °C as previously described (31). The concentration of free [Ca21] in
kinase reactions was calculated as described by Imai and Okeda (34)
using the equation: p[Ca21] 5 2 pH 2 7.28 1 log([EGTA]added/
[CaCl2]added 2 1). Km and Vmax values were determined from Line-
weaver-Burk double-reciprocal plots using SigmaPlot software (SPSS
Inc., Chicago, IL).
Phosphorylation of MLCK by p60Src in Vitro
Purified MLCKs were dialyzed and brought to 0.1 mg/ml concentra-
tion using reaction buffer containing 25 mM Tris-HCl, pH 7.5, 20 mM
KCl, 5 mM Mg21 acetate, 0.5 mM leupeptin. Phosphorylation of MLCK
diluted in reaction buffer was started by adding 0.2 mM ATP, 10 mCi/ml
[g-32P]ATP and 75 units/ml recombinant p60src kinase (Upstate Bio-
technology, Inc., Lake Placid, NY; final concentrations). Synthetic
MLCK-1 peptides were used for p60src phosphorylation assays at 0.1
mg/ml final concentration. In certain experiments, a putative specific
p60src inhibitor, PP-2 (Calbiochem-Novabiochem Corp., La Jolla, CA),
was added to reaction tubes at 500 nM final concentration. The phos-
phorylation reaction was performed at 22 °C, and 10-ml aliquots of
reaction mixture were applied onto cellulose phosphate filters P81
(Whatman, UK) at specified periods of time. The filters were washed to
remove unincorporated label, and specific incorporation of 32P into
MLCK was determined by scintillation counting. The p60Src phospho-
rylation of the MLCK synthetic peptides as substrates was performed
during 30 min at 22 °C under the same conditions. For scintillation
counting, synthetic MLCK peptides were spotted onto nitrocellulose,
and unbound radioactive label was washed out with solution containing
20% methanol and 2% disodium pyrophosphate. After completion of the
phosphorylation reaction, phospho-MLCKs were aliquoted and stored
at 280 °C until use in kinase assays.
Tryptic Cleavage and MALDI TOF Analysis of
MLCK-1 Phosphopeptides
A 200-ml aliquot of MLCK-1 (0.3 mg/ml) phosphorylated by p60src in
vitro was partially digested by incubation with trypsin (1:100 w/w) for
5 min at room temperature in buffer containing 50 mM Tris-HCl, pH
7.5, 5 mM EGTA, 5 mM MgCl2. The reaction was terminated by adding
phenylmethylsulfonyl fluoride at 2 mM final concentration. The reaction
mixture was lysed in SDS-sample buffer, peptides were separated on
SDS-polyacrylamide gel electrophoresis, and phosphotyrosine peptides
were identified by autoradiography and Western blot with anti-phos-
photyrosine antibody. A portion of the polyacrylamide gel containing a
major 55-kDa MLCK-1 tryptic peptide, which incorporated 32P and
cross-reacted with anti-phosphotyrosine antibody, was excised and fur-
ther processed. After 3 3 30 min washes in distilled water, the gel piece
was trimmed and the phosphopeptide incorporated into gel was sub-
jected to destaining and complete trypsinolysis. Gel destaining required
the addition of 100 ml of 1:1 (v/v) acetonitrile:25 mM ammonium bicar-
bonate for ;30 min. The gel was then dried down completely using a
Speed Vac concentrator (Savant), and further trypsinolysis was per-
formed. The gel was incubated overnight at 37 °C with 1 ml of trypsin
solution (0.1 mg/ml in 1% acetic acid) and 25 ml of 25 mM ammonium
bicarbonate, pH 7.8. After trypsinolysis, the MLCK peptides were
eluted from the gel with a 1:1 (v/v) acetonitrile:water, 5% trifluoroacetic
acid solution and concentrated to several microliters by Speed Vac. This
peptide mixture was then analyzed by mass spectrometry. Mass spectra
were acquired on a Kratos Axima CFR (Manchester, United Kingdom)
time-of-flight mass spectrometer. Briefly, an aliquot of the peptide
digest (0.3 ml) was placed on the sample plate followed by the addition
of 0.3 ml of saturated ammonium sulfate and 0.3 ml of matrix solution
(saturated solution of a-cyano-4-hydroxycinnamic acid in 1:1 (v/v) eth-
anol:water). The mixture was air-dried (;10 min), and the sample plate
was inserted into the mass spectrometer.
RESULTS
Kinetic Characteristics of Recombinant Endothelial Cell
MLCK Splice Variants—The domain organization of the endo-
thelial cell MLCK isoforms is schematically presented in Fig.
1A and demonstrates that the two endothelial isoforms:
MLCK-1 and MLCK-2 are identical with the exception of the
FIG. 1. Baculovirus expression and purification of recombi-
nant MLCK isoforms. A, schematic representation of the domain
organization of recombinant endothelial MLCK-1, MLCK-2, and
smooth muscle MLCK expressed in baculovirus system. Depicted are
the actin-binding domain, catalytic core, (catalyst), the regulatory seg-
ment containing the inhibitory and calmodulin-binding domains, and
the kinase-related protein (KRP) domain. The unique N-terminal por-
tion of the endothelial MLCK isoforms contains putative SH3- and
SH2-binding domains. A 69-residue fragment (hatched region) contain-
ing a putative SH2-binding domain and the potential p60Src phospho-
rylation sites (Tyr464, Tyr471, and Tyr485) is not expressed by either
MLCK-2 or SM MLCK. The histidine tag (HIS) has been introduced at
the C termini of recombinant MLCKs for purification purposes. B,
purification of recombinant MLCK expressed in the baculovirus expres-
sion system using metal ion chromatography. The Coomassie Blue-
stained gel demonstrates the results of MLCK purification using
MLCK-1 as an example. Lane 1, molecular weight standards; lane 2,
control cell lysate; lane 3, total lysate of MLCK-1-producing cells; lane
4, flowthrough fraction after Ni-NTA column chromatography; lane 5,
purified MLCK-1 eluted from Ni-NTA resin with elution buffer contain-
ing 100 mM imidazole (see “Materials and Methods”). Lanes 6 and 7
represent the purified MLCK-2 and smooth muscle MLCK, respec-
tively, after identical purification procedures. C, Western blot verifica-
tion of recombinant MLCK isoforms using anti-MLCK antiserum D119.
Lane 1 represents control Sf9 lysate; lanes 2–4 depict anti-MLCK
immunoreactivity of purified recombinant MLCK-1, MLCK-2, and
smooth muscle MLCK, respectively, after elution from the Ni-NTA
column.
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deletion of a 69-residue stretch encoded by a single exon in
MLCK-2 (28). The baculovirus-expressed and -purified MLCK
isoforms (MLCK-1, MLCK-2, and SM MLCK) were analyzed by
gel electrophoresis and revealed protein bands with expected
sizes 214, 206, and 150 kDa, respectively (Fig. 1B), which
reacted on the Western blot with MLCK-specific D119 anti-
serum (Fig. 1C). After purification and rigorous sequencing
analysis, the three recombinant MLCK isoforms were exam-
ined for their intrinsic enzymatic properties. Both EC MLCK-1
and EC MLCK-2 exhibited comparable Vmax values (11.9 6 3.2
and 10.9 6 1.8 mmol/min/mg, respectively), which were slightly
reduced compared with the rabbit SM MLCK isoform (17.0 6
2.5 mmol/min/mg) (Table I). The Km values reflecting substrate
affinity were not significantly different among the three recom-
binant MLCK preparations, whereas the K0.5 calmodulin was
higher for the EC MLCK isoforms (0.49 and 0.42 nM) compared
with the rabbit SM MLCK isoform (0.21 nM) (Table I). Overall,
the Km, Vmax, K0.5 calmodulin values for the baculovirus-ex-
pressed endothelial MLCK-1 and MLCK-2 splice variants are
in good agreement with published values for MLCK activity
derived from other tissues (24, 35–37). Furthermore, all three
recombinant MLCK isoforms possess identical substrate spec-
ificity and preferentially phosphorylate Ser19 and Thr18 of reg-
ulatory MLC20 (Table I), because the substitution of Ala for
either Ser19 alone or both Ser19 and Thr18 in the MLC mutants
resulted in dramatic reduction in MLC20 phosphorylation.
These results are in complete agreement with the previously
reported preferred sequential phosphorylation of Ser19 followed
by phosphorylation at the MLC second site (Thr18), which is
phosphorylated more slowly than Ser19 and requires relatively
high concentrations of myosin light chain kinase (2).
In Vitro Phosphorylation of MLCK Isoforms by p60Src—Aug-
mentation of tyrosine protein phosphorylation in endothelial
cells in vivo correlates with increased phosphotyrosine content
in MLCK immunoprecipitates, increased MLCK activity, and
increased MLC phosphorylation (26, 38). More recently, EC
MLCK has been shown to be stably associated with p60Src and
a well recognized p60Src substrate, the actin-binding protein
cortactin (26). To further characterize the role of tyrosine phos-
phorylation in EC MLCK regulation, the three recombinant
MLCK isoforms were used as substrates for in vitro phospho-
rylation catalyzed by p60Src. EC MLCK-1 exhibited substantial
time-dependent p60src-catalyzed incorporation of radioactive
phosphate (Fig. 2), whereas p60src-mediated 32P incorporation
did not occur in either MLCK-2, the EC MLCK splice variant,
lacking the 69-amino acid stretch containing the p60src consen-
sus site, nor in SM MLCK, which completely lacks the novel N
terminus (Fig. 2). The 32P incorporation into MLCK-1 was
essentially abolished by the specific p60src kinase inhibitor
PP-2 (250 nM). However, all three MLCK isoforms exhibited
low level of 32P incorporation even in the absence of p60src
(0.63 6 0.21 mol of PO4/mol of protein) consistent with the
MLCK autophosphorylation previously described for smooth
muscle MLCK (39, 40). This was confirmed by heat treatment
of the MLCK preparations (70 °C for 5 min), which completely
abolished incorporation of 32P into MLCK in the absence of
p60src (data not shown). The preferential p60src-catalyzed phos-
phorylation of MLCK-1 compared with other MLCK isoforms
strongly suggested that the specific site of tyrosine phosphoryl-
ation of endothelial MLCK by p60src resides within the 69-
amino acid residue stretch in the N-terminal part of the MLCK
molecule encoded by a single exon (28), which is not expressed
in MLCK-2. However, the stoichiometry of phosphate incorpo-
ration into MLCK-1 catalyzed by p60src (2.32 6 0.32 mol of
PO4/mol of protein) strongly suggested the potential presence
of a secondary tyrosine residue within MLCK-1, which may
also be phosphorylated by p60src.
Identification of p60src Phosphorylation Sites within MLCK-
1—To search for tyrosine phosphorylation site(s) within
MLCK-1, we applied mass spectroscopy analysis of tryptic frag-
ments obtained from MLCK-1 phosphorylated by p60src. As an
initial step, a limited trypsinolysis of radiolabeled phospho-
MLCK-1 was performed, and tyrosine phosphorylation site(s)
mapped to the tryptic fragment with an approximate molecular
weight of 55 kDa based on autoradiography data and Western
blot analysis with anti-phosphotyrosine antibody (inset, Fig.
3A). Mass spectrometric analysis of MLCK-1 peptides obtained
after complete tryptic digestion of a 55-kDa MLCK-1 fragment
FIG. 2. Phosphorylation of MLCK-1, MLCK-2, and SM MLCK by
p60Src in vitro. Purified recombinant MLCK-1 (left panel) and
MLCK-2 (middle panel) and SM MLCK (right panel) expressed in the
baculovirus system were phosphorylated using purified p60Src kinase as
outlined under “Materials and Methods.” The insets depict the repre-
sentative autoradiograms of time-dependent 32P incorporation into
each MLCK isoform in the presence of [32P]ATP and p60Src. The graphs
demonstrate the time dependence of 32P incorporation into MLCK-1,
MLCK-2, and SM MLCK incubated in the presence of p60Src alone
(solid lines) or in combination with 500 nM PP-2, a specific inhibitor of
p60Src (broken lines) or in the absence of p60Src (dotted lines). The
results obtained in four independent experiments are expressed as the
stoichiometry of 32P incorporation into MLCK.
TABLE I
Kinetic properties and substrate specificity of recombinant MLCK-1, MLCK-2, and SM MLCK isoforms
Purified recombinant MLCK isoforms were used for in vitro kinase assay. Reaction mixtures were incubated with purified wild type MLC20 as
substrate, as described under “Materials and Methods.” Km and Vmax were derived from double-reciprocal plots. K0.5 CaM was determined at 5 3
1026 M smooth muscle MLC20 final concentration and at saturating Ca
21 concentration. Kinase activity of recombinant MLCKs toward wild type
(wt) and mutant MLC20 is expressed as 10
28 mol of phosphate incorporated per mg of MLCK per min. The concentrations of wild type and mutant
MLC20 were 5 3 10
26 M. The kinetic data represent the mean 6 S.D. of at least five separate experiments. The difference in K0.5 CaM and Vmax
between the EC MLCK and SM MLCK isoforms is statistically significant (p , 0.01).






MLC wt MLC mutants
Thr18/Ser19 Thr18/Ala19 Ala18/Ala19
1026 mol/mg/min 1029 mol/mg/min
MLCK-1 11.9 6 3.2 0.49 6.5 6 2.2 330 6 8 3.8 6 0.7 0.4 6 0.2
MLCK-2 10.9 6 1.8 0.43 7.2 6 2.8 361 6 8 3.7 6 1 0.6 6 0.5
SM MLCK 17.0 6 2.5 0.21 5.2 6 0.4 859 6 25 9.8 6 3.2 2.6 6 0.9
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revealed a group of peptides corresponding to the N-terminal
portion of MLCK-1 (Fig. 3A). Furthermore, we identified a
single characteristic peak (Fig. 3A) not seen in the digests of
MLCK-1 preincubated with ATP without p60src (data not
shown). This peak has m/z ratio 2486 corresponding to the
theoretical mass of the tryptic peptide 457–476 of MLCK-1
(457QEGSIEVYEDAGSHYLCLLK476) with two incorporated
phosphate groups (underlined). MALDI TOF analysis allowed
isotopic resolution of the m/z 2486 peak (isotopic variants with
m/z ratios 2484.9, 2485.9, and 2486.9, respectively) further
supporting mapping of the peak to the diphospho-(457–476)-
MLCK-1 fragment. To further prove phosphorylation of sites
Y464 and Y471 by p60src, we used synthetic peptides
460SIEVYEDAGSHYLCLL475 and 478RTRDSGTYSCTASNA492
corresponding to amino acid residues 460–475 and 478–492 of
full-length MLCK-1 protein, respectively, for in vitro p60src
phosphorylation assay (Fig. 3B). Only the peptide containing
Y464 and Y471 was readily phosphorylated in the presence of
p60src, whereas another candidate peptide containing the po-
tential p60src consensus phosphorylation site, Y485, as well as
irrelevant peptide PEKVPPPKPATPDFRSVL (residues 968–
985 of MLCK-1), which lacks tyrosine residues, were not phos-
phorylated. The relatively low stoichiometry of p60src-mediated
phosphate incorporation into peptide 460–475 (;0.015 mol of
PO4/mol of peptide, 10-min reaction) suggests that other
MLCK-1 epitope(s) in proximity to amino acid residues 460–
475 may be required for the optimal p60src activity. As recently
demonstrated, the interaction of the p60src SH3 domain with
the ligand sequence of the substrate is important for activation
of the catalytic domain and autophosphorylation (41), and the
addition of an SH3 domain ligand to a substrate peptide in-
creases its phosphorylation 10-fold via lowering of the Km value
of the substrate and kinase activation (42). Thus, putative
SH3- and SH2-binding domains present in MLCK-1 N-termi-
nal portion (Fig. 1A) may be important for p60src-catalyzed
MLCK-1 phosphorylation, and further studies are underway to
address this question. Finally, mass spectrometry analysis of
the fragments obtained after cyanogen bromide cleavage of the
MLCK-1 suggested that the two phosphate groups are con-
tained within the Lys1721-Met1761 EC MLCK fragment (data
not shown) consistent with the presence of the EC MLCK-1
autophosphorylation sites Thr1748 and Ser1760, which are ho-
mologous to the previously described SM MLCK autophospho-
rylation sites Thr803 and Ser815 (39).
Differential Activation of MLCK-1 and MLCK-2 by p60src-
mediated Phosphorylation—To explore whether phosphoryla-
tion by p60src alters endothelial MLCK-1 enzymatic properties,
MLCK-1 samples were preincubated with either ATP and
p60src (“phospho-MLCK”) or ATP alone (“dephospho-EC
MLCK”), followed by assessment of in vitro kinase activity.
Phosphorylation of EC MLCK-1 by p60src increased EC
MLCK-1 kinase activity 2-fold (Fig. 4), whereas the enzymatic
activities of EC MLCK-2 and SM MLCK were not affected by
p60src and were comparable to that measured for EC MLCK-1
in the absence of p60src. These results are again consistent with
the inability of p60src to phosphorylate EC MLCK-2 (as shown
FIG. 3. Identification of the tyrosine phosphorylation sites
within the N-terminal 55-kDa MLCK-1 tryptic fragment. The
p60src-catalyzed phosphorylation of the 55-kDa tryptic MLCK-1 frag-
ment was detected by autoradiography and immunoreactivity with
anti-phosphotyrosine antibody (upper inset). After excision from the gel,
the phosphoprotein was subjected to complete trypsinolysis as de-
scribed under “Materials and Methods,” and the peptide digest was
analyzed using mass spectrometry. A, high mass spectrum resolution of
the peak with an average m/z ratio 2486, which mathematically cor-
responds to tryptic fragment 457–476 of MLCK-1 with two incorporated
phosphate groups. Shown are peaks with m/z ratios 2484.9, 2485.9,
and 2486.9 corresponding to isotopic variants of the diphosphorylated
MLCK-1 457–476 peptide. B, in vitro p60Src-catalyzed phosphorylation
of synthetic peptides consisting of amino acids 968–985, 460–475, and
478–492 of MLCK-1. Each peptide was tested in kinase assay as
outlined under “Materials and Methods.” Each point represents the
mean 6 S.E. of three experiments. *, results are significant p , 0.005.
FIG. 4. Effect of phosphorylation of endothelial MLCK by
p60src on MLCK activity in vitro. A, kinase activity of MLCK-1 after
60-min incubation with either p60src (solid bars) or vehicle (cross-
hatched bars). The MLC kinase assay utilized recombinant rabbit
smooth muscle MLCs as substrate as described under “Materials and
Methods.” B and C are similar to A with the exception that MLCK-2 or
SM MLCK were used in each reaction mixture. MLCK-2 and SM MLCK
incubated with (solid bars) or without (open bars) p60src under identical
conditions were also tested for kinase activity. Removal of Ca21 from
the kinase reaction mixture with EGTA or the addition of specific
MLCK inhibitor ML-7 (5 3 1026 M) abolishes MLCK-1, MLCK-2, and
SM MLCK activity. MLCK-catalyzed 32P incorporation into myosin
light chains in the presence of Ca21 and calmodulin in the reaction
mixture as described under “Materials and Methods” was taken as
100% MLCK activation. Each point represents the mean 6 S.E. of at
least three experiments. *, results are significant p , 0.005.
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in Fig. 2) and indicate a significant enhancement of MLCK-1
kinase activity by p60src-mediated phosphorylation. Enzymatic
activity of all three isoforms was Ca21/CaM-dependent, be-
cause chelation of free Ca21 with 2 mM EGTA (Fig. 4) or
removal of calmodulin from the kinase reaction mixture (data
not shown) completely abolished MLC phosphorylation cata-
lyzed by either phospho- or dephospho-MLCK-1 preparations
by MLCK-2 and SM MLCK. An inhibitor of smooth muscle
MLCK activity, ML-7 (5 3 1026 M) also abolished the enzymatic
activity of EC MLCK-1 (phospho- and dephospho-), EC
MLCK-2, and SM MLCK (Fig. 4). Finally, phosphorylation of
MLCK-1 by p60src did not alter Ca21/CaM-dependent regula-
tion, because the values for half-maximal activation of phos-
pho- and dephospho-MLCK-1 determined over a range of free
Ca21 concentrations (1028 to 1025 M) were comparable (pCa
6.56 versus pCa 6.50, respectively) despite an increase of ;2-
fold in enzymatic activity toward MLC20 in the phospho-
MLCK-1 preparation (Fig. 5). These data suggest that, al-
though similar Ca21 concentrations are required for MLCK-1
activity, tyrosine phosphorylation promotes increased MLC
phosphorylation at lower Ca21 concentrations within the cells.
DISCUSSION
In contrast to smooth muscle, only the high molecular weight
MLCK isoform (208–214 kDa) is expressed in endothelium
(18–20, 22). Molecular cloning of MLCK from human endothe-
lial cells (20) revealed a high molecular weight MLCK variant
containing a unique 922-residue N-terminal domain not ex-
pressed in the low molecular weight MLCK isoform, which is
abundantly expressed in smooth muscle. Comparison of the
cDNA encoding human high and low molecular weight MLCKs,
when combined with results of chromosome mapping of human
MLCK to single locus with chromosomal localization to 3qcen-
q21 (6), suggests that mammalian MLCK genomic organization
is highly similar to the “gene within a gene” organization of the
avian smooth muscle/nonmuscle MLCK gene expressing two
size class MLCK variants and one nonkinase protein (KRP),
which are encoded by exons 1–31, 15–31, and 29A-31, respec-
tively (17, 43). The complexity of the human MLCK genomic
organization was recently further emphasized by the detection
of five splice variants of high molecular weight MLCK in non-
muscle and smooth muscle tissues using RT-PCR approaches
(28). These data, which elucidated the considerable expression
of EC MLCK-2, were strongly consistent with the potential
functional diversity of the expressed smooth muscle and non-
muscle MLCK proteins. Among endothelial cell MLCK splice
variants, the MLCK-1 and MLCK-2 appear to be preferentially
expressed (28), although all five have been identified in tissues.
Using purified recombinant MLCK-1 and MLCK-2 expressed
in a baculovirus system, we have now characterized for the first
time the kinetic parameters of the high molecular weight
MLCK isoforms from human endothelial cells. Comparisons of
the Vmax and Km of these high molecular weight isoforms to
recombinant rabbit uterine smooth muscle MLCK reveal very
similar enzymatic properties of the three MLCK isoforms.
However, a 2-fold increase in K0.5 calmodulin observed in endo-
thelial MLCK splice variants, may suggest a lower sensitivity
of the intracellular EC MLCK for regulation by Ca21/calmod-
ulin as compared with SM MLCK.
A number of protein kinases, including cAMP-dependent
protein kinase A, protein kinase C, Ca21/CaM-dependent pro-
tein kinase II, and p21-activated kinase have been demon-
strated to phosphorylate the smooth muscle MLCK isoform in
vitro and in vivo (44–47). Serine/threonine phosphorylation
within MLCK calmodulin-binding domain results in a 10-fold
increase in KCaM reflecting a 3.5-fold decrease in the associa-
tion rate and a 6-fold increase in the dissociation rate between
MLCK and Ca21/CaM (3, 45, 46, 48, 49) and thus reduced
MLCK enzymatic activity. In turn, phosphorylation by p21-
activated kinase decreases MLCK-1 catalytic activity by ;50%
via decrease in maximum velocity (Vmax) without affecting
KCaM (47). In addition, Thr
803, Ser815, and Ser823 of the smooth
muscle MLCK isoform undergo autophosphorylation in vitro
also resulting in decreased MLCK affinity to Ca21/calmodulin
(39).
In contrast to serine/threonine phosphorylation of SM MLCK
and EC MLCK, which attenuates MLCK activity (3, 20, 31, 46,
48), information is limited regarding phosphorylation sites
within the MLCK molecule, which serve to enhance its enzy-
matic activity. Phosphorylation of smooth muscle MLCK by
mitogen-activated protein kinase in vitro has been reported to
stimulate smooth muscle MLCK activity (50), although we
have not yet found mitogen-activated protein kinase to affect
EC MLCK activity in this manner. However, recent studies
have defined the involvement of tyrosine phosphorylation in
EC MLCK regulation (26, 27, 51). Augmentation of protein
tyrosine phosphorylation increased MLC20 phosphorylation
and cell contraction in endothelial cells, which strongly corre-
lated with an increase in MLCK phosphotyrosine content, en-
hanced MLCK enzymatic activity, and the stable association of
EC MLCK with activated p60src (26). Our present results ap-
pear to be consistent with the hypothesized novel role of the
unique N terminus in EC MLCK regulation via tyrosine phos-
phorylation. We now demonstrate for the first time the in vitro
phosphorylation of the full-length EC MLCK-1 by p60Src kinase
on Tyr464 and Tyr471, post-translational modifications not ob-
served in the EC MLCK-2 splice variant lacking the 69-residue
stretch (amino acids 436–505) in the N terminus, which is
encoded by a single exon deleted in the EC MLCK-2 isoform
(28). Our future studies using site-directed mutagenesis ap-
proach are aimed at the determination of the sequence of phos-
phorylation events and the role of each tyrosine phosphoryla-
tion site in the regulation of MLCK-1.
In summary, we have characterized the kinetic properties of
endothelial MLCK splice variants and demonstrated a novel
mechanism of MLCK-1 regulation by p60src phosphorylation.
The phosphorylation sites (Tyr464 and Tyr471) are located
within unique N-terminal domain (436–505) of endothelial
MLCK-1 isoform not expressed in smooth muscle MLCK or in
the alternatively spliced endothelial isoform MLCK-2. Consist-
ent with this finding, only MLCK-1 activity is regulated by
FIG. 5. Effect of p60src-mediated MLCK-1 phosphorylation on
Ca21-dependent MLCK-1 activation. The enzymatic activities of
p60src-treated MLCK-1 (solid line) or MLCK-1 incubated with vehicle
and referred as dephospho-MLCK-1 (broken line) were measured in the
presence of 5 3 1027 M calmodulin over a range of Ca21 concentrations
(1028 to 1025 M) as described under “Materials and Methods.” The
maximal activity of phospho-MLCK-1 observed in the presence of 1026
M [Ca21] was taken as 100%. Maximal activation of dephospho-MLCK-1
(incubated at 1026 M [Ca21]) represents 55% of phospho-MLCK-1 activ-
ity. Each point represents the mean 6 S.E. of at least three experi-
ments. *, results are significant p , 0.005. EC50 values for Ca
21 de-
pendence of dephospho- and phospho-MLCK-1 activation are outlined
by vertical lines.
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p60src-catalyzed phosphorylation. These data demonstrate the
importance of the novel N-terminal domain in the specific
regulation of the MLCK isoform present in nonmuscle cells. As
we have previously demonstrated, the tyrosine phosphoryla-
tion of EC MLCK increases its association with both p60src
kinase, as well as with the actin-binding protein and the p60src
substrate cortactin (26), we speculate that MLCK-1 tyrosine
phosphorylation may be involved in contractile complex scaf-
folding and contribute to Ca21 sensitization of the endothelial
contractile apparatus. Based on our data, we speculate that
p60src-catalyzed tyrosine phosphorylation contributes to the
local and selective activation of endothelial cell MLCK-1 under
submaximal Ca21 concentrations providing a mechanism that
may tightly orchestrate critical cytoskeletal rearrangements
and ultimately the cellular contraction, which is critical for
endothelial cell-dependent biological processes, such as vascu-
lar barrier regulation, transendothelial leukocyte diapedesis,
and angiogenesis.
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